{"keywords":[],"alternate_symbols":[],"type":"Disease","medgen_id":"C0282160","name":"Aplasia cutis congenita (disease)","symbol":"ACC","alternate_names":["Aplasia cutis congenita","Aplasia cutis congenita nonsyndromic","Congenital absence of skin","Congenital defect of skull and scalp","Congenital scars","Cutis aplasia","Scalp defect congenital"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001057\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007145\"}","{\"db\":\"OMIM\",\"id\":\"107600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1114\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Aplasia+Cutis+Congenita/549\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aplasia cutis congenita\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001057\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aplasia cutis congenita\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001057\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital absence of skin\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001057\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital scars\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001057\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cutis aplasia\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007145\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"107600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"id":"425"}
{"keywords":[],"alternate_symbols":[],"type":"Finding","medgen_id":"C0029454","name":"Osteopetrosis","alternate_names":["Marble bone disease"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011002\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011002\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Marble bone disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011002\",\"ref_field\":\"name\"}"],"attribute_content":[],"id":"28913"}
{"keywords":[],"alternate_symbols":["PAH","PHT"],"type":"Disease","medgen_id":"C4552070","name":"Pulmonary Hypertension, Primary, 1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301658\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1485\",\"@Source\":\"BookShelf\"}]}}","symbol":"PPH1","alternate_names":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0024533\"}","{\"db\":\"OMIM\",\"id\":\"178600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"422\"}","{\"db\":\"OMIM\",\"id\":\"178600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PAH\"}","{\"db\":\"OMIM\",\"id\":\"178600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PHT\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0024533\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"178600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"id":"3581"}
{"keywords":[],"alternate_symbols":[],"type":"Disease","medgen_id":"C4015357","name":"Mental retardation, autosomal dominant 31","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28448108\",\"@Source\":\"PubMed\"},{\"$\":\"NBK426063\",\"@Source\":\"BookShelf\"}]}}","symbol":"MRD31","alternate_names":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0018580\"}","{\"db\":\"OMIM\",\"id\":\"616158\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"438213\"}","{\"db\":\"Orphanet\",\"id\":\"438216\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK426063\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616158\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"PURA-related neurodevelopmental disorders include PURA syndrome, caused by a heterozygous pathogenic sequence variant in PURA, and 5q31.3 deletion syndrome, caused by a genomic 5q31.3 deletion encompassing all or part of PURA.PURA-related neurodevelopmental disorders are characterized by moderate-to-severe neurodevelopmental delay with absence of speech in most and lack of independent ambulation in many. Early-onset problems can include hypotonia, hypothermia, hypersomnolence, feeding difficulties, excessive hiccups, recurrent central and obstructive apneas, epileptic seizures, abnormal nonepileptic movements (dystonia, dyskinesia, and dysconjugate eye movements), and abnormal vision. Congenital heart defects, urogenital malformations, skeletal abnormalities, and endocrine disorders occur, but are less common.","id":"32585"}
{"keywords":[],"alternate_symbols":[],"type":"Disease","medgen_id":"C2931244","name":"Craniometaphyseal dysplasia, autosomal recessive","gard_id":"1582","symbol":"CMDR","alternate_names":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009035\"}","{\"db\":\"OMIM\",\"id\":\"218400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1522\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1582\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0009035\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"218400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"id":"855"}
{"keywords":[],"alternate_symbols":[],"type":"Disease","medgen_id":"CN186176","name":"Lamellar ichthyosis","gard_id":"10803","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301593\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1420\",\"@Source\":\"BookShelf\"}]}}","alternate_names":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0017778\"}","{\"db\":\"Orphanet\",\"id\":\"313\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10803\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1420\",\"ref_field\":\"public_definition\"}"],"attribute_content":[],"public_definition":"Autosomal recessive congenital ichthyosis (ARCI) encompasses several forms of nonsyndromic ichthyosis. Although most neonates with ARCI are collodion babies, the clinical presentation and severity of ARCI may vary significantly, ranging from harlequin ichthyosis, the most severe and often fatal form, to lamellar ichthyosis (LI) and (nonbullous) congenital ichthyosiform erythroderma (CIE). These phenotypes are now recognized to fall on a continuum; however, the phenotypic descriptions are clinically useful for clarification of prognosis and management. Infants with harlequin ichthyosis are usually born prematurely and are encased in thick, hard, armor-like plates of cornified skin that severely restrict movement. Life-threatening complications in the immediate postnatal period include respiratory distress, feeding problems, and systemic infection. Collodion babies are born with a taut, shiny, translucent or opaque membrane that encases the entire body and lasts for days to weeks. LI and CIE are seemingly distinct phenotypes: classic, severe LI with dark brown, plate-like scale with no erythroderma and CIE with finer whiter scale and underlying generalized redness of the skin. Affected individuals with severe involvement can have ectropion, eclabium, scarring alopecia involving the scalp and eyebrows, and palmar and plantar keratoderma. Besides these major forms of nonsyndromic ichthyosis, a few rare subtypes have been recognized, such as bathing suit ichthyosis, self-improving collodion ichthyosis, or ichthyosis-prematurity syndrome.","id":"18703"}
{"keywords":[],"alternate_symbols":[],"type":"Disease","medgen_id":"C2749861","name":"Mitochondrial DNA depletion syndrome, encephalomyopathic form, with renal tubulopathy","gard_id":"13200","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24741716\",\"@Source\":\"PubMed\"},{\"$\":\"NBK195854\",\"@Source\":\"BookShelf\"}]}}","symbol":"MTDPS8A","alternate_names":["MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)","MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC, WITH RENAL TUBULOPATHY, AUTOSOMAL RECESSIVE","RRM2B-Related Mitochondrial DNA Depletion Syndrome, Encephalomyopathic Form, with Renal Tubulopathy"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012792\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"255235\"}","{\"db\":\"OMIM\",\"id\":\"604712.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"604712.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME 8A (ENCEPHALOMYOPATHIC TYPE WITH RENAL TUBULOPATHY)\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC, WITH RENAL TUBULOPATHY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13200\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mitochondrial+DNA+depletion+syndrome%2C+encephalomyopathic+form%2C+with+renal+tubulopathy/8900\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK195854\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612075\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"RRM2B-related mitochondrial disease can be grouped by disease pathogenesis, phenotype, and mode of inheritance into two major types: mitochondrial DNA (mtDNA) depletion and multiple mtDNA deletions. Mitochondrial DNA depletion usually manifests as severe multisystem disease (encephalomyopathy with proximal renal tubulopathy) and is often fatal in early life. Inheritance is autosomal recessive. Multiple mtDNA deletions cause tissue-specific cytochrome c oxidase (COX) deficiency. Inheritance can be either autosomal recessive (with progressive external ophthalmoplegia [PEO] and multisystem involvement manifesting during early childhood/adulthood) or autosomal dominant (with less severe, often tissue-specific manifestations [e.g., chronic PEO] developing in later adulthood). Other rarer phenotypes are Kearns-Sayre syndrome (KSS) and mitochondrial neurogastrointestinal encephalopathy (MNGIE).","id":"2810"}
{"disease_mechanism_id":"273","keywords":[],"disease_mechanism":"loss of function","alternate_symbols":["VHL"],"type":"Disease","medgen_id":"C0019562","name":"Von Hippel-Lindau syndrome","gard_id":"7855","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301636\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1463\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ES, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24893135\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NANETS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3419007\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"KCRNC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24319509\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","symbol":"VHLS","alternate_names":["VHL syndrome"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008667\"}","{\"db\":\"OMIM\",\"id\":\"193300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"892\"}","{\"db\":\"OMIM\",\"id\":\"193300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"VHL\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000314230\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528276\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552165\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552183\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552245\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553528\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562500\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569658\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7855\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Von+Hippel-Lindau+syndrome/7416\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"46659004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1463\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"193300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":[],"public_definition":"Von Hippel-Lindau (VHL) syndrome is characterized by hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts, and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL syndrome and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.","id":"6116"}
{"disease_mechanism_id":"273","keywords":[],"disease_mechanism":"loss of function","mode_of_inheritance":"imprinting disorder","alternate_symbols":[],"type":"Disease","medgen_id":"C0162635","name":"Angelman syndrome","gard_id":"5810","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301323\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1144\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111049\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Eurogentest, 2008\",\"@Type\":\"Translational/Evidence-based\",\"URL\":{\"$\":\"http://www.eurogentest.org/web/files/public/unit3/ClinicalUtilityGeneCards/Indication%20criteria%20-%20AS.pdf\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESHG/ASHG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25782669\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"27467454\",\"@Source\":\"PubMed\"}}]}","symbol":"AS","alternate_names":["HAPPY PUPPET SYNDROME","Happy puppet syndrome (formerly)"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007113\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"72\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAPPY PUPPET SYNDROME\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226643\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260593\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331374\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503131\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507771\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508896\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508937\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509438\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519582\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521642\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522320\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525860\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525867\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527540\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529013\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530102\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531722\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552178\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552326\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552341\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556577\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556612\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558215\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558216\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558805\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558906\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5810\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260593\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Angelman+Syndrome/452\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"angelman-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"76880004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1144\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"attribute_content":["{\"Attribute\":{\"$\":\"AS is caused by disruption of maternally imprinted UBE3A located within the 15q11.2-q13 Angelman syndrome/Prader-Willi syndrome (AS/PWS) region.\",\"@Type\":\"mode of inheritance\"},\"XRef\":{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000501320\"}}"],"public_definition":"Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and a unique behavior with an inappropriate happy demeanor that includes frequent laughing, smiling, and excitability. Microcephaly and seizures are also common. Developmental delays are first noted at around age six months; however, the unique clinical features of AS do not become manifest until after age one year, and it can take several years before the correct clinical diagnosis is obvious.","id":"404"}
{"keywords":[],"disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","alternate_symbols":[],"type":"Disease","medgen_id":"C0002986","name":"Fabry disease","gard_id":"6400","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"}]}"],"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","id":"1790"}
